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Summary Serum thyroxine was significantly higher in 59 patients with hepatocellular carcinoma than in
normal subjects, patients with uncomplicated cirrhosis (48), or other primary tumours with or without hepatic
metastases (50). Elevated thyroxine levels appeared attributable to high levels of thyroxine binding globulin
which showed a positive linear correlation with serum thyroxine in all groups studied. Despite this
hyperthyroxinaemia all patients appeared clinically euthyroid and, consistent with this, T3 was elevated in
only one patient and the free thyroxine index was normal in all. Amongst a group of 25 cirrhotic patients
who were followed-up for between 12 and 72 months, there was a striking dissociation between the TBG
values of those destined to develop HCC and those who did not. In the former group TBG rose steadily with
time whereas in the latter group levels remained stable, or, more often, fell. The rises in TBG occurred prior
to any clinical signs of tumour development and may be one of the earliest serological changes to occur
during carcinogenesis in the cirrhotic liver.
Changes in the serum levels of thyroid hormones and their
binding proteins in patients with cirrhosis are well-
documented (Chopra et al., 1974; Hepner & Chopra, 1979;
Lumholtz et al., 1978; Nomura et al., 1975). Most studies
have shown a normal thyroxine (T4) level with impaired
conversion to triiodothyronine (T3) resulting in low levels of
T3 and high levels of reverse T3 (rT3). Despite this, clinical
evidence of hypothyroidism is uncommon and direct
measurement of free T4 (fT4) or the free thyroxine index has
usually given normal values (Green et al., 1970; Liewendahl
et al., 1983). In contrast, hyperthyroxinaemia has been
described in some patients with hepatocellular carcinoma
(HCC), a frequent complication of long-standing cirrhosis
(Gershengorn et al., 1976; Kalk et al., 1982; Nelson, 1979).
The hyperthyroxinaemia has been attributed to elevated
levels of thyroxine binding globulin (TBG) but whether
abnormalities of other thyroid binding proteins such as
albumin and prealbumin are also involved has not been
determined. There are also no data on how levels of TBG
change before diagnosis of HCC or whether such changes
are specific for HCC or occur generally in malignant disease.
In the present study we have measured the serum thyroid
hormones together with their binding proteins in a large
series of patients with HCC and various control groups
including uncomplicated cirrhosis and other primary
tumours with or without hepatic metastases. In addition we
measured serum TBG in serial samples available from the
Unit's serum bank in a further group of cirrhotic patients, to
determine at what stage during the development of HCC the
abnormalities can first be detected.
Patients and methods
The 59 patients with HCC (46 males, 13 females) were aged
17-74 years. In each case the diagnosis was established
histologically or by the combination of an elevated serum
alphafoetoprotein (AFP) (>500ngml-1) and characteristic
arteriographic appearances. Forty-two had underlying
cirrhosis (alcoholic 13, cryptogenic 8, primary biliary 1,
chronic active hepatitis 18, and haemochromatosis 2). The
three control groups comprised 48 patients with
uncomplicated cirrhosis (18 alcoholic, 9 cryptogenic and 9
primary biliary, 8 chronic active hepatitis, 2 secondary
biliary 1 a-I antitrypsin deficiency, and 1 Wilson's disease),
50 patients with a variety of other malignant neoplasms (26
of whom had documented hepatic metastases) and 20
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healthy volunteers recruited from the ho6pital staff. None of
the subjects studied was receiving drugs known to interfere
with thyroid function. In all patients with HCC the serum
samples studied were those collected at the time of diagnosis
and prior to any treatment.
The stored serial sera (which had been frozen once and
not previously thawed before the assay) came from patients
included in a prospective study of the development of HCC
in cirrhosis (Zaman et al., 1985). These comprised 25
patients with histologically confirmed cirrhosis, none of
whom at the time of the first available samples had any
clinical or scanning evidence of HCC, or an elevated serum
AFP level. In each individual case at least 2 and up to 4
serum samples were available over a follow-up period of
between 1 and 6 years. Of these 25 patients, 10 ultimately
developed HCC. Nine were male, with a mean age of 45
(range 33-59 years) and they represented all those patients
with HCC in whom serial retrospective samples were
available. The aetiology of the underlying cirrhosis (which
had been diagnosed for a mean of 36 months (range 12-80
months)) was alcoholic 3, chronic active hepatitis 4,
cryptogenic 2, and primary biliary cirrhosis 1.
The 15 patients who did not develop HCC were selected at
random from the serum bank, the only criterion being that
they should have serum samples available over a similar
period to those who did develop HCC. Eight died following
complications of cirrhosis other than HCC, and 7 were alive
and without evidence of HCC development at the time of
analysis. Ten were male, with a mean age of 49 (range 17-71
years). The aetiology of the underlying cirrhosis (diagnosed
between 13 and 72 (mean 45)) months previously was
alcoholic 6, chronic active hepatitis 3 and primary biliary
cirrhosis 6. None of these patients was included in the first
part of the study.
Triiodothyronine (T3), thyroid stimulating hormone (TSH)
and AFP were measured by radioimmunoassay using com-
mercially available kits (Amersham UK plc) as were TBG
and T4 (Corning, Immophase). Serum albumin and
prealbumin were measured by single radial immunodiffusion
according to the method of Mancini et al.(1965) (Nor
Partigen and M Partigen plates, Behring, UK). The normal
ranges quoted are those given by the manufacturer and are
based on several hundred normal subjects. Accuracy within
the various methods was established by the manufacturers
based on correlations with alternative methods of assay for
each component. Correlation coefficients between the
methods used here and the alternative procedures ranged
from 0.912 (TBG immophase assay vs. nephelometry) to
0.976 (T4, immophase assay vs. solid phase RIA method). We
included a small control group to confirm that the assays
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gave a comparable reference range in our hands. Duplicate
assays were performed on each serum sample, the result
being acceptable where the coefficient of variation was 5%
or less. Data are presented as mean+s.d., and the Mann-
Whitney 'U'-test used to assess the differences between the
various groups. Correlations between TBG and T4 and T3
were assessed using logarithmic transformation of the TBG
values on account of the skewed distribution of TBG values
in the normal population (Gershengorn et al., 1976; Kalk et
al., 1982).
Results
Total serum T4 was elevated in 13 (22%) of those with HCC
and in 3 patients (6%), to a minor degree, in the
uncomplicated cirrhosis group. None of those with other
primary malignant tumours had elevated T4 levels (Figure
1). Comparison of T4 levels in HCC patients showed no
significant difference between those with and without
cirrhosis. The free thyroxine index (T4/TBG ratio) was
within the normal range (2.2-6.1) as were the T3 levels in all
the cirrhotic and normal subjects and in all but 2 of the
HCC patients in whom it was measured.
TBG was at the upper limit of the normal range or
elevated in all those with high T4 levels (Figure 2) whereas
serum albumin (mean 33+6.9, normal range 36-52gl-')
and prealbumin (mean 120+59, normal range 250-
300mgl-1) were normal or low. TBG levels were
significantly higher in HCC patients than in those with
uncomplicated cirrhosis (28±+11 gml- compared to
20.4+7.6upgmlP-, P<0.01) and the control subjects
(21.95+2.91pgml-P, P<0.01). Significant differences were
also observed in respect of T4 values between HCC and
uncomplicated cirrhotic patients and control subjects where
T4 values were 126+57nmoll-1 in the HCC patients
compared to 86.3+45.2nmoll-1 in those with un-
complicated cirrhosis (P<0.05) and 100+14.4nmoll-1 in
the control group (P<0.05). The HCC patients with high
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Figure 2 Distribution of serum TBG concentrations in patients
with HCC, uncomplicated cirrhosis, and healthy control subjects.
The dashed horizontal lines represent the reference range. (0)
represents patients with elevated T4 levels.
TBG levels were not distinguishable from those in whom
levels were normal in respect of any of the clinical or
pathological features recorded.
Levels of TBG were linearly related to serum total T4 in
patients with HCC (r=0.75, P<0.001), cirrhosis (r=0.65,
P<0.0025) and, as expected, in normal subjects (r=0.50,
P<0.0025) (Figure 3). Serum T3 levels showed a positive
linear correlation with TBG in the 21 cirrhotic patients in
whom it was measured (r=0.89, P<0.001) but not in the
other two groups (r=0.4, P>0.05 for HCC, r=0.35,
P>0.05 for normal subjects).
Serial measurements ofTBG
Ten cirrhotic patients, in whom serial samples had been
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Figure 1 Distribution of serum T4 concentrations in patients
with HCC (59), uncomplicated cirrhosis (48), and healthy control
subjects (20). The dashed horizontal lines represent the reference
range.
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Figure 3 Correlations between serum T4 and logTBG
concentrations in patients with HCC [y=39.2x-38.5, r=0.75,
P<0.001], uncomplicated cirrhosis ('cirrhosis') [y=9.78x-5.81,
r=0.65, P<0.0025J, and healthy control subjects ('control')
Ly=6.59x-0.99, r=0.5, P<0.0025].
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obtained prospectively over a period of t
years, developed HCC. Measurements of T
of these patients showed there to have
progressive rise of between 6 and 50% per
period prior to the diagnosis of HCC (Fi
values within the normal range in the firsi
sample (time=0, Figure 4) and the rises c
mainly within the normal range which was
4 patients.
In contrast to those patients ultimately
levels of TBG in those not developing HC
(as seen in the 7 who eventually died) or
(Figure 4). Three cirrhotic patients (with P
show no evidence of HCC development als(
rising TBG levels but in only one di
consecutive samples.
Eight of the 10 patients who developc
serum AFP positive (>50ngml-1, a level
in uncomplicated cirrhosis). Estimation of s
in the same stored samples examined for 1
in 6 of these the rise in TBG occurred b
months before the serum AFP exceeded 50
TBG levels were elevated 5 years before
HCC and 2 years before AFP levels exce
range. In the 3 remaining patients both prc
taneously.
Discussion
Our figure of a 22% frequency for hyper
patients with HCC is of the same order as
Kalk et al. (1982) in South African black:
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Figure 4 Serial changes in TBG in 25 cirrh(
( ---- 0) developed HCC and 15 (O ---
died without HCC or remain alive with no evi
each instance the diagnosis of HCC was establ
of the last serum sample (0).
between 1 and 6 mean and standard deviation of the total T4 levels in the
BG in the serum HCC patients in the two studies are also similar. The fact
been a steadily that in the current study the mean T4 value in HCC patients
r annum over the is significantly higher than in the control group, while in the
igure 4). All had study of Kalk et al. (1982) they are not, may be related to
t available serum the wider normal range. Using a reference based on our own
bserved occurred small healthy control group, 50% of the HCC patients had
exceeded in only elevated T4 levels. The demonstrated rise in TBG levels in
the preclinical stage of the disease must also mean that the
developing HCC, percentage of patients found with elevated levels is
XC tended to fall dependent on the time of diagnosis.
remained stable The clinical impression that the patients with hyper-
'BC) who to date thyroxinaemia were euthyroid was supported by the T3 and
o had episodes of T4/TBG levels which were not elevated. T3 levels in the
d this occur in cirrhotic patients of the present series were normal rather
than low as reported in the literature (Hepner & Chopra,
ed HCC became 1979; Lumholtz et al., 1978). This may reflect the generally
seldom exceeded good condition of those patients who were selected from
serum AFP levels cases of cirrhosis attending the out-patient clinic.
rBG showed that The finding that the total T4 level is linearly related to log
etween 4 and 24 serum TBG over a wide range of T4 levels in both
ngml-1. In one, uncomplicated cirrhosis and those with HCC suggests that
the diagnosis of the hyperthyroxinaemia is attributable to an elevation of
eded the normal TBG levels and not albumin or prealbumin which were
)teins rose simul- either normal or low. In 2 other systematic studies of TBG
in HCC, elevated levels were found in 10% of North
American patients (Gershengorn et al., 1976) and 37% of
South African blacks (Kalk et al., 1982) compared to our
figure of 22%. These differences may again reflect differing
definitions of the 'normal range'. The lower figure of 10%
thyroxinaemia in may, as pointed out by Kalk et al., be misleading since 37%
that reported by of this group's patients had levels above the mean plus two
s (18%) and the standard deviations of their control population. Again using
the normal range derived from our own small control group
of 20 subjects 53% of our patients had elevated TBG levels,
compared with 29% of cirrhotics.
High levels of TBG did not occur in patients with other
primary tumours including those cases with hepatic
metastases, suggesting that the phenomenon is fairly specific
for HCC. Nonetheless, not all HCC patients had elevated
levels but we were unable to distinguish between those with
high and normal levels on the basis of any clinical features
or the underlying hepatic pathology.
Amongst the patients with cirrhosis steadily rising TBG
levels were largely confined to those destined to develop
HCC even if the normal range was not exceeded. Such
changes occurring at a time when there is no tumour
detectable by conventional methods may represent the first
evidence of a very small HCC or possibly a developing
preneoplastic cell population.
t Whether the increase in TBG levels is attributable to
structurally normal TBG or some variant is not known
though forms of TBG having abnormal T4 binding and
affinity characteristics have been described in patients with
liver disease (Gartner et al., 1984). In this regard it is
interesting that with increasing T4 levels, the relative increase
in TBG binding in both HCC and uncomplicated cirrhosis is
higher than that seen in normal subjects (Figure 4). Thus at
low concentrations of TBG T4 levels tend to be lower in the
HCC and cirrhotic subjects whereas at high levels the reverse
is true. Whether variant forms of TBG which are subject to
allosteric modification occur in these two groups can only be
established by purification and kinetic study of the species
obtained from them.
The linear correlation between T3 and TBG found in
c'rrhftir nntient-, hilt nnt thqe, with H4CC w:aq aiirnri,mno A
60 80 ~ , lll\Jl 1jLklIL3 UUL WILLI 1 1-% wab buiFiibing.
t 60 80 differential effect of the disease on the binding characteristics
i) of one or more variant forms of TBG may be implicated.
otic patients. Ten Up to seven distinct variant forms of TBG have been
--O) have either described in the sera of healthy subjects and some
idence thereof. In pathological states (Takamatsu & Refetoff, 1986). These
lished at the time differ in electrophoretic mobility, heat resistance, pH
stability as well as in affinity for T3 and T4. It is possible316 A. ALEXOPOULOS et al.
that among this family, forms which display enhanced
affinity for T4 and T3 may predominate in HCC and
cirrhosis.
Although TBG is normally produced by the liver (Glinoer
et al., 1976a,b) the site of production in this situation is
unknown and although most workers have considered the
possibilities that either non-tumorous liver is stimulated to
produce TBG by tumour or production by the tumour itself,
there is also the possibility of production by a preneoplastic
cell population. Recently two groups have demonstrated that
HepG2, an established liver cell line derived from a child
with a hepatoblastoma synthesises and secretes TBG which
is immunologically identical to native human sera TBG
(Bartalena et al., 1984; Murata et al., 1985).
Whilst the degree of overlap between the TBG levels in
cirrhotic patients with and without HCC means that the
absolute level of TBG is not a clinically useful marker of
HCC, the dissociation between rising levels in the former
group and falling or stable levels in the latter may offer the
possibility of a screening test for early HCC. This is particu-
larly so as it appears that some changes can be detected
whilst AFP levels are still normal. In view of the results
obtained in this study, validation of such a test based on
changes in TBG levels would be a long term study.
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